13,665 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Aware Super Pty Ltd as trustee of Aware Super

Aware Super Pty Ltd as trustee of Aware Super purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 13,665 shares of the biopharmaceutical company's stock, valued at approximately $3,216,000.

A number of other hedge funds also recently bought and sold shares of the company. Orion Portfolio Solutions LLC lifted its stake in shares of Alnylam Pharmaceuticals by 14.8% in the third quarter. Orion Portfolio Solutions LLC now owns 3,541 shares of the biopharmaceutical company's stock worth $974,000 after buying an additional 457 shares in the last quarter. MML Investors Services LLC raised its holdings in Alnylam Pharmaceuticals by 5.7% in the 3rd quarter. MML Investors Services LLC now owns 3,086 shares of the biopharmaceutical company's stock worth $849,000 after acquiring an additional 166 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in Alnylam Pharmaceuticals by 43.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 1,211 shares of the biopharmaceutical company's stock valued at $329,000 after acquiring an additional 368 shares in the last quarter. Sanctuary Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 4,558 shares of the biopharmaceutical company's stock valued at $1,254,000 after purchasing an additional 2,181 shares during the last quarter. Finally, Tidal Investments LLC raised its stake in shares of Alnylam Pharmaceuticals by 75.1% in the third quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company's stock worth $5,650,000 after purchasing an additional 8,811 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded up $4.06 during midday trading on Friday, hitting $234.56. 601,349 shares of the company traded hands, compared to its average volume of 872,674. The stock has a market cap of $30.51 billion, a price-to-earnings ratio of -108.09 and a beta of 0.30. The firm has a 50 day moving average of $249.14 and a 200-day moving average of $256.89. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ALNY. Sanford C. Bernstein reduced their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Morgan Stanley lowered their price objective on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, StockNews.com lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $315.58.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the business's stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.